189 related articles for article (PubMed ID: 31380290)
1. Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC.
Liu X; Zhang M; Liu X; Sun H; Guo Z; Tang X; Wang Z; Li J; Li H; Sun W; Zhang Y
Front Oncol; 2019; 9():663. PubMed ID: 31380290
[TBL] [Abstract][Full Text] [Related]
2. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
3. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
4. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
Front Oncol; 2020; 10():717. PubMed ID: 32500026
[TBL] [Abstract][Full Text] [Related]
5. Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma.
Falegan OS; Ball MW; Shaykhutdinov RA; Pieroraio PM; Farshidfar F; Vogel HJ; Allaf ME; Hyndman ME
Metabolites; 2017 Feb; 7(1):. PubMed ID: 28165361
[TBL] [Abstract][Full Text] [Related]
6. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
7. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
8. Study on potential markers for diagnosis of renal cell carcinoma by serum untargeted metabolomics based on UPLC-MS/MS.
Wang J; Yang WY; Li XH; Xu B; Yang YW; Zhang B; Dai CM; Feng JF
Front Physiol; 2022; 13():996248. PubMed ID: 36523562
[No Abstract] [Full Text] [Related]
9. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
11. [Urinary metabolomics study of renal cell carcinoma based on gas chromatography-mass spectrometry].
Zhang L; Li L; Kong H; Zeng F
Nan Fang Yi Ke Da Xue Xue Bao; 2015 May; 35(5):763-6. PubMed ID: 26018279
[TBL] [Abstract][Full Text] [Related]
12. Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics.
Bifarin OO; Gaul DA; Sah S; Arnold RS; Ogan K; Master VA; Roberts DL; Bergquist SH; Petros JA; Fernández FM; Edison AS
J Proteome Res; 2021 Jul; 20(7):3629-3641. PubMed ID: 34161092
[TBL] [Abstract][Full Text] [Related]
13. Urine-Based Metabolomics and Machine Learning Reveals Metabolites Associated with Renal Cell Carcinoma Stage.
Bifarin OO; Gaul DA; Sah S; Arnold RS; Ogan K; Master VA; Roberts DL; Bergquist SH; Petros JA; Edison AS; Fernández FM
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944874
[TBL] [Abstract][Full Text] [Related]
14. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
[TBL] [Abstract][Full Text] [Related]
15. LC-MS based urine untargeted metabolomic analyses to identify and subdivide urothelial cancer.
Yang M; Liu X; Tang X; Sun W; Ji Z
Front Oncol; 2023; 13():1160965. PubMed ID: 37256175
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
Cheng X; Liu X; Liu X; Guo Z; Sun H; Zhang M; Ji Z; Sun W
Front Oncol; 2018; 8():494. PubMed ID: 30450336
[No Abstract] [Full Text] [Related]
17. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
18. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract][Full Text] [Related]
19. LC-MS-based urine metabolomics analysis of chronic subdural hematoma for biomarker discovery.
Sun J; Ou Y; Liu X; Sun H; Guo Z; Qi F; Lan Y; Liu W; Sun W
Proteomics Clin Appl; 2024 Jan; 18(1):e2200107. PubMed ID: 37697649
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED
JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
